Grantham, Mayo, Van Otterloo & Co (GMO)
CNMD icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s CONMED CNMD Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-71,600
Closed -$4.1M – 764
2020
Q1 		$4.1M Buy
+71,600
New +$6.6M 0.03% 271
2019
Q3 		– Sell
-10,500
Closed -$898K – 737
2019
Q2 		$898K Buy
+10,500
New +$863K 0.01% 539
2019
Q1 		– Sell
-5,500
Closed -$353K – 705
2018
Q4 		$353K Hold
5,500
– – ﹤0.01% 471
2018
Q3 		$436K Buy
+5,500
New +$425K ﹤0.01% 452

Other funds holding CNMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s CNMD Position: Q2 2020 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of CONMED (CNMD) in Q2 2020, closing a stake of 71,600 shares — an estimated $4.1M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in CNMD in Q3 2018 and held it in 4 quarters. The position peaked at $4.1M in Q1 2020. 227 funds tracked by Wall St. Rank hold CNMD as of Q2 2020.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining CONMED position as of Q2 2020 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 71,600 CONMED shares in Q2 2020, an estimated $4.1M.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in CONMED in Q3 2018 and held it in 4 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s CONMED position peaked at $4.1M in Q1 2020.
  • 227 funds tracked by Wall St. Rank held CONMED as of Q2 2020.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2020, filed 13 Aug 2020.